Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to assess …

Increased evidence suggests that somatic mutations in the ligand-binding domain of estrogen
receptor [ER (ERα/ESR1)] are critical mediators of endocrine-resistant breast cancer …

Background Mutations in the estrogen receptor alpha (ERα) 1 gene (ESR1) are frequently
detected in ER+ metastatic breast cancer, and there is increasing evidence that these …

The breakdown of the blood‐brain barrier (BBB) is related to the occurrence and deterioration
of neurological dysfunction in ischemic stroke, which leads to the extravasation of blood‐…

Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived xenografts …

1-Diaryl moieties are core structures in a wide range of bioactive and pharmaceutical
compounds. Transition-metal catalysis is a convenient approach to accessing these invaluable …

Chiral boronic esters are a class of versatile building blocks. We describe herein an asymmetric
nickel-catalyzed borylative coupling of terminal alkenes with nonactivated alkyl halides. …

Estrogen receptor alpha (ER/ESR1) is frequently mutated in endocrine resistant ER-positive
(ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the …

Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic
studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show …

Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3
pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using …